Takeda Sells Yaroslavl Plant Amid Russian Mental Health Drug Boom
Takeda Pharmaceuticals has announced the sale of its plant in Yaroslavl, Russia, to AO 'GK Binergya'. This move comes amidst a significant increase in demand for antidepressants and anxiety drugs in the country, with Russians purchasing 17.1 million packages worth RUB 12.9 billion in 2024, a 36% rise from the previous year.
The deal, which includes the transfer of rights to commercialize non-core drugs and imported drugs in the Eurasian Economic Union countries, was driven by Takeda's shareholders who sought to reduce the company's presence in the Russian market. This decision follows a similar move by Bristol Myers Squibb, which sold its rights to a Russian drug manufacturer collaborating with 'Nizhpharm' in spring 2023.
The Yaroslavl plant, with an annual production capacity of 90 million ampoules and over 3 billion tablets, is a significant asset. It produces drugs such as 'Ninlaro', 'Actovegin', 'Voncitin', and 'Calcium-D3 Niomed'. Notably, sales of 'Ninlaro' in Russia doubled year-on-year in January-August 2025, with around 9,000 packages worth RUB 1.8 billion sold. The plant's investment stands at over €117 million.
Takeda's Russian subsidiary has agreed to the sale, which comes at a time when the company's revenue in Russia grew by 23% to RUB 33 billion in 2024, with a net profit increase of over three times to RUB 2.2 billion.
The sale of the Yaroslavl plant to AO 'GK Binergya' by Takeda Pharmaceuticals reflects the dynamic changes in the Russian pharmaceutical market, driven by increased demand for mental health drugs and strategic decisions by international pharmaceutical companies.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
